Trial Profile
Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Trastuzumab Plus Paclitaxel or Endocrine Therapy in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab-Based Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Denifanstat (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2023 Planned primary completion date changed from 30 Jul 2023 to 30 Jul 2024.
- 31 May 2022 Planned End Date changed from 30 Jul 2022 to 30 Jul 2024.